-
Mashup Score: 0Elective Discontinuation May Be Possible With Larotrectinib in TRK Fusion–Positive Sarcomas - 7 hour(s) ago
Pediatric patients with TRK fusion–positive sarcomas may be able to safely discontinue larotrectinib and resume treatment if needed without sacrificing response.
Source: www.onclive.comCategories: General Medicine NewsTweet
Elective discontinuation after responses to larotrectinib was shown to be safe and feasible in pediatric patients with TRK fusion–positive infantile fibrosarcoma or other soft tissue sarcomas. @myESMO #Sarcoma #ESMORareCancers25 https://t.co/KipOXgmg38 https://t.co/T1OxpbGxub